Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.88%
0%
-5.88%
6 Months
14.29%
0%
14.29%
1 Year
-10.11%
0%
-10.11%
2 Years
-79.62%
0%
-79.62%
3 Years
188.24%
0%
188.24%
4 Years
-97.71%
0%
-97.71%
5 Years
0%
0%
0.0%
Talis Biomedical Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-33.24%
EBIT Growth (5y)
-44.68%
EBIT to Interest (avg)
-120.56
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.17
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
56.62%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.91
EV to EBIT
0.26
EV to EBITDA
0.26
EV to Capital Employed
1.51
EV to Sales
-12.58
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
592.20%
ROE (Latest)
-92.66%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Jun 2024
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 3 Schemes (2.53%)
Foreign Institutions
Held by 8 Foreign Institutions (0.28%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'24 - QoQ
Jun'24
Mar'24
Change(%)
Net Sales
0.00
0.10
-100.00%
Operating Profit (PBDIT) excl Other Income
-8.50
-8.90
4.49%
Interest
0.00
0.00
Exceptional Items
-1.00
-5.00
80.00%
Consolidate Net Profit
-8.80
-13.00
32.31%
Operating Profit Margin (Excl OI)
0.00%
-125,287.70%
12,528.77%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2024 is -100.00% vs -50.00% in Mar 2024
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2024 is 32.31% vs 3.70% in Mar 2024
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
0.40
3.70
-89.19%
Operating Profit (PBDIT) excl Other Income
-65.00
-101.10
35.71%
Interest
0.00
0.00
Exceptional Items
-2.80
-3.60
22.22%
Consolidate Net Profit
-62.00
-113.00
45.13%
Operating Profit Margin (Excl OI)
-159,638.30%
-30,861.40%
-12,877.69%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is -89.19% vs 0.00% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 45.13% vs 41.15% in Dec 2022
About Talis Biomedical Corp. 
Talis Biomedical Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






